Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 1997

View Archived Issues

Shaman: Q3 1997 highlights

TNFR:Fc evaluated in patients with heart failure

Sankyo synthesizes azole aromatase inhibitors

ACAT inhibitors described by Sankyo in patent literature

Suntory's penems are active against MRSA

New 5-LO inhibitors from Meiji Milk

Regeneron: Q3 1997 highlights

T Cell Sciences: Q3 1997 highlights

Xoma: Q3 1997 highlights

Guilford: Q3 1997 highlights

Neurex: Q3 1997 highlights

Promising clinical results reported for Avakine

Immunomedics issued U.S. patent for imaging and treatment of infections and inflammation

LeukoSite, Warner-Lambert and Kyowa Hakko chemokine drug discovery collaboration

TK inhibitors under development at Dr. Karl Thomae

CCK/gastrin receptor ligands from James Black Foundation

Antiinflammatory CRF analogues prepared at U of California

Conformationally constrained arginal thrombin inhibitors prepared at Lusofarmaco/Guidotti

Pharmacokinetics, peripheral antihistaminic and central effects of rupatadine in humans

Alendronate and etidronate prevent steroid-induced osteoporosis

Minocycline associated with marked long-term efficacy in early RA

Preclinical antiinflammatory effects demonstrated for CT-3

Novo Nordisk files for HRT product in U.S.

Cubist acquires rights to daptomycin

Atacand launched in Sweden

Second drug from Inhale/Baxter collaboration enters clinical testing

New formulation of amiodarone shows favorable hemodynamic effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Rare earth: Biomarin to use global reach post-$4.8B Amicus buy
BioWorld
Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...